This page is for HCPs* and ORDMs** in Great Britain. Information on this page is aligned to the Great Britain Summary of Product Characteristics.
Information about adverse event reporting can be found towards the bottom of the page
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Menu
Close
Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
COMIRNATY Omicron XBB.1.5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2.
The use of this vaccine should be in accordance with official recommendations and at least 3 months since the last prior COVID-19 Vaccine1.
Comirnaty Omicron XBB.1.5 may be administered concomitantly with seasonal influenza vaccine.
| Dosage | 30 mcg of raxtozinameran |
| Injection Volume per Dose | 0.3 mL |
| Dilution | No dilution required |
| Vial size | 2ml |
| Doses per Vial | 1 dose per vial |
Prescribing Information:
Great Britain: Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection, single dose vial COVID-19 mRNA Vaccine
For more details about the other presentations of COMIRNATY Omicron XBB.1.5, for use in the National Immunisation Programme, please refer to the Summary of Product Characteristics or visit the COMIRNATY Education site.
Adverse Event Reporting
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via a Yellow card. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store and include the batch/Lot number if available.
Alternatively, adverse events of concern in association with COMIRNATY can be reported to Pfizer Medical Information on 01304 616161 or via www.pfizersafetyreporting.com.
Please do not report the same adverse event(s) to both systems as all reports will be shared between Pfizer and MHRA (in an anonymised form) and dual reporting will create unnecessary duplicates.
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Marketing Authorisation
Holder: BioNTech
Manufacturing GmbH
COMIRNATY, COMIRNATY Omicron XBB.1.5, are based on BioNTech proprietary mRNA technology, developed by both BioNTech and Pfizer.
The product information provided in this site is intended only for Healthcare Professionals and Other Relevant Decision Makers resident in the United Kingdom.
This website is brought to you by Pfizer Limited, a company registered in England and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent CT13 9NJ.
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
PP-CMR-GBR-0512. January 2024
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024